Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Supernus Pharmaceuticals reported record revenue for both the fourth quarter and full year 2025 but moved from profit to loss due mainly to acquisition-related costs. Total revenues reached $211.6 million in Q4 2025, up 21% year over year, and $719.0 million for 2025, up 9%.
Growth products were the main driver, with combined revenues of $161.3 million in Q4 and $521.8 million for 2025, rising 45% and 40%. Newer assets performed strongly: ONAPGO generated $8.9 million in Q4 sales after its April launch and ZURZUVAE collaboration revenue was $32.8 million. However, 2025 GAAP operating results swung to a $62.3 million loss and net loss of $38.6 million, largely reflecting approximately $72.9 million in costs tied to the Sage Therapeutics acquisition and higher amortization and contingent consideration. Adjusted operating earnings were $158.7 million. Cash, cash equivalents and marketable securities were $308.7 million at year-end, after funding the Sage deal. For 2026, Supernus guides to total revenues of $840–$870 million, GAAP operating earnings of $0–$30 million, and adjusted operating earnings of $140–$170 million.
SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig reported a set of stock transactions involving restricted stock units and common shares of SUPN. On February 19, 2026, she exercised 4,475 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share as the units vested.
That same day, she conducted open-market sales of common stock in two blocks: 1,217 shares at a weighted average price of $50.31 (with individual trades between $49.83 and $50.71) and 3,258 shares at a weighted average price of $51.27 (with trades between $50.98 and $51.56). These sales, totaling 4,475 shares, were made under a Rule 10b5-1 trading plan adopted on May 15, 2025, and left her with 0 shares of common stock directly owned after the reported transactions.
Supernus Pharmaceuticals reported that Senior Vice-President & CFO Timothy C. Dec received new equity awards. He was granted employee stock options for 17,500 shares at a price of $0.00 per share, which vest in four equal annual installments beginning on February 18, 2027. He also received 3,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments starting on the same date and settled in common stock upon vesting. Following these awards, he directly holds 1,638 shares of common stock, including an aggregate of 392 shares acquired through the company’s Employee Stock Purchase Plan.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported equity awards on February 18, 2026. He received an option to buy 13,500 shares of common stock and 3,000 restricted stock units, both granted at $0.00 per share as compensation.
The option and RSUs vest in four equal annual installments beginning on February 18, 2027. Following these awards, Bhatt directly holds 14,900 shares of common stock, which includes 392 shares acquired through the company’s employee stock purchase plan, along with the new option and RSU positions.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin received new equity awards. On February 18, 2026, he was granted an employee stock option for 13,500 shares and 3,000 restricted stock units, both at no exercise cost per the filing.
The option vests in four equal annual installments starting February 18, 2027. Each restricted stock unit converts into one share of common stock and also vests in four equal annual installments beginning on that date. Following these awards, Rubin directly holds 11,284 shares of common stock, including 269 acquired through the employee stock purchase plan.
SUPERNUS PHARMACEUTICALS, INC. reported that SVP and Chief Technical Operations Officer Frank Mottola received new equity awards. He was granted employee stock options for 13,500 shares and 3,000 restricted stock units on February 18, 2026, both at a price of $0.00 per share.
The options vest in four equal annual installments beginning on February 18, 2027. Each restricted stock unit converts into one share of common stock and is settled in stock upon vesting, also in four equal annual installments starting on February 18, 2027. Following these grants, Mottola directly holds 15,724 shares of common stock, which include 228 shares acquired through the company’s employee stock purchase plan, along with the 13,500 options and 3,000 restricted stock units.
SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar received a grant of employee stock options for 341,610 shares on February 18, 2026. The options were awarded as a grant/award acquisition and vest in four equal annual installments beginning on February 18, 2027.
GEMAYEL GEORGES reported acquisition or exercise transactions in this Form 4 filing.
Supernus Pharmaceuticals director Georges Gemayel reported receiving new equity awards. On February 18, 2026, he was granted 2,989 restricted stock units and 4,977 director stock options, both at a price of $0.0000 per unit. The RSUs and options each vest on February 18, 2027.
Supernus Pharmaceuticals director Carrolee Barlow reported equity awards consisting of restricted stock units and stock options. On February 18, 2026, Barlow acquired 2,989 restricted stock units and 4,977 director stock options as compensation awards, with no cash paid per unit or option.
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Both the restricted stock units and the options vest on February 18, 2027, at which time the restricted stock units will be settled in common stock and the options will become exercisable.
Sensenig Bethany reported acquisition or exercise transactions in this Form 4 filing.
SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig received new equity awards in the form of restricted stock units and stock options. She was granted 2,989 restricted stock units, each representing one share of Supernus common stock, and 4,977 director stock options.
The restricted stock units will be settled in common stock when they vest on February 18, 2027. The director stock options also vest on February 18, 2027. These awards increase Sensenig’s equity-based stake in the company but do not involve any open‑market share purchases or sales.